Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases

Rakesh C Kukreja PhD, Fadi N Salloum PhD, Anindita Das PhD, Saisudha Koka PhD, Ramzi A Ockaili PhD, Lei Xi MD

Phosphodiesterase type-5 (PDE-5) is an enzyme that catalyzes the hydrolytic degradation of cyclic GMP – an essential intracellular second messenger that modulates diverse biological processes in living cells. Three selective inhibitors of PDE-5 – sildenafil, vardenafil and tadalafil – have been successfully used by millions of men worldwide for the treatment of erectile dysfunction. Also, sildenafil and tadalafil are currently approved for the treatment of pulmonary hypertension. Recent powerful basic science data and clinical studies suggest potential nonurological applications of PDE-5 inhibitors, including ischemia/reperfusion injury, myocardial infarction, cardiac hypertrophy, cardiomyopathy, heart failure, stroke, neurodegenerative diseases and other circulatory disorders including Raynaud’s phenomenon. Future carefully controlled clinical trials would hopefully expedite their expanding therapeutic use in patients with cardiovascular disease.

Key Words: Cardiovascular disease; Ischemia/reperfusion injury; Phosphodiesterase-5 inhibitors

Phosphodiesterase (PDE) is an enzyme that catalyzes the hydrolytic degradation of cyclic AMP (cAMP) and/or cyclic GMP (cGMP) – the two essential intracellular second messengers that modulate diverse biological processes in living cells (1,2). A total of 11 PDE families, along with several splice variants, have been identified (2,5). The distribution of the PDE isozymes varies across different tissues and cell types, and most likely the different subcellular compartments (2,5). Another important difference among the PDE isoforms is their substrate specificity for cAMP versus cGMP. Such a diversified tissue distribution and selectivity in hydrolyzing cAMP/cGMP may provide a molecular basis for PDE in participating in the complex functional processes in the body. PDE-5 was originally identified and purified from rat platelets (6) and lungs (7) in 1980. Subsequent studies showed that PDE-5 is widely present in vascular and bronchial smooth muscles, platelets, renal tubules and lung tissues. Recent studies from our laboratory and others have confirmed PDE-5A expression in isolated cardiomyocytes from mice (8) and dogs (9). PDE-5 messenger RNA was also detected in human heart samples (10).

For the majority of medical professionals, PDE-5 may be best known as the molecular target of three well-advertised PDE-5 inhibitors – sildenafil (Viagra, Pfizer Canada Inc), vardenafil (Levitra, Bayer Inc, Canada) and tadalafil (Cialis, Eli Lilly Canada Inc) – that have been prescribed by urologists worldwide to treat erectile dysfunction. In fact, sildenafil and tadalafil were among the 11 most popular prescription drugs dispensed in the United States in 2006. Sildenafil citrate was developed by Pfizer Inc, and in March 1998, was the first PDE-5 inhibitor approved by the United States Food and Drug Administration (FDA) for the treatment of ED. Vardenafil, co-developed by Bayer and GlaxoSmithKline, has a duration of action greater than 36 h and 72 h, respectively. Tadalafil was co-developed by ICOS Corporation and Eli Lilly, and its long-acting inhibitory effect on PDE-5 may last for up to 36 h (13).

The mechanism of action for the three PDE-5 inhibitors involves increased tissue levels of cGMP, which causes smooth muscle relaxation and vasodilation. Because erection is largely a hemodynamic event, which is regulated by vascular tone and blood flow balance in the penis (14), and because cGMP modulates vascular tone, PDE-5 inhibitors could enhance erectile function by blocking the enzymatic hydrolysis of cGMP. The recent advancing basic and clinical studies suggest some very promising new applications of PDE-5 inhibitors, far beyond their urological scope, which are reviewed as follows.

ISCHEMIA/REPERFUSION INJURY AND MYOCARDIAL INFARCTION

Myocardial ischemia/reperfusion injury occurs in a wide spectrum of patients – ranging from survivors of out-of-hospital cardiac arrest to acute myocardial infarction (MI) victims and patients undergoing cardiac surgery – and represents a major public health burden. The infarct size needs to be limited because for patients with MI who do not die from out-of-hospital arrhythmias, the prognosis is dependent on the amount of heart muscle that is lost as a result of ischemia/reperfusion injury. Thus, there is a compelling need to protect the heart muscle in patients experiencing a heart attack. The first study showing a powerful preconditioning-like effect of sildenafil against myocardial ischemia/reperfusion injury in an in vivo rabbit model was published by our research group in 2002 (15). This discovery of the infarct-limiting effect of sildenafil has been duplicated in several models including mouse hearts (16-18), infant rabbit hearts (19) and rat hearts (20-22). A similar cardioprotective effect has been observed with vardenafil in rabbits (23) and tadalafil in rats (24), which reinforces the idea that PDE-5 inhibitors as a class had cardioprotective effects against ischemia/reperfusion injury. The anti-ischemic effects of sildenafil were also observed against ischemia/reperfusion-triggered ventricular arrhythmias (20,23) as well as improvement of posts ischemic ventricular contractile function (19-21). In addition to the preconditioning-like effects of these drugs, two recent studies showed the infarct-limiting effect of sildenafil or vardenafil when administered just before reperfusion (26,27). Likewise, tadalafil reduced infarct size when given 30 min to 120 min before coronary occlusion through protein kinase G (PKG)-dependent generation of H2S in the myocardium (28). The duration of cardioprotection from tadalafil remained until 36 h to 40 h after a single dose, and repeat administration at 36 h and 72 h extended protection until 108 h (29).

The protective effect of sildenafil against necrosis and apoptosis was also observed in isolated cardiomyocytes subjected to simulated ischemia/reoxygenation (30), suggesting that the vascular effects of this drug or participation of other cell types, eg, endothelial cells or fibroblasts, were not necessarily required to protect against cell death.

Department of Internal Medicine, Division of Cardiology, Virginia Commonwealth University Pauley Heart Center, Richmond, Virginia, USA
Correspondence: Dr Rakesh C Kukreja, Departments of Medicine, Physiology, Biochemistry and Emergency Medicine, Division of Cardiology, Virginia Commonwealth University Pauley Heart Center, Box 982081, 1101 East Marshall Street, Room 7-020D, Richmond, Virginia 23298 USA.
Telephone 804-628-5521, fax 804-828-8700, e-mail rakesh@vcu.edu

©2011 Pulsus Group Inc. All rights reserved
Exp Clin Cardiol Vol 16 No 4 2011
Sildenafil combined with low-dose atorvastatin – another widely used drug for lowering cholesterol – has been shown to have a potent protective effect against MI in rats (22). These studies suggest that PDE-5 inhibitors, either alone or possibly in combination with statins, may be useful as adjunct therapy in patients undergoing coronary artery bypass grafting, coronary angioplasty or heart transplantation. Based on our animal data, we believe that timely administration of clinically relevant doses of ED drugs can significantly reduce heart muscle damage in patients after a major heart attack and improve chances of survival. In addition, there is a potential application of these studies in preventing multiple organ damage that occurs following cardiac arrest/ resuscitation or shock. Clinically, there was an interesting observational cohort study using prescription-event monitoring in the United Kingdom, which showed no evidence for an increased risk of MI or ischemic heart disease in patients taking sildenafil during the first months of treatment. Also, the mortality in sildenafil takers was lower than in the general population (30).

The mechanism by which PDE-5 inhibitors exert cytoprotective effects following ischemia/reperfusion is not completely understood. We first hypothesized that the vasodilatory action of PDE-5 inhibitors, particularly in vivo, could release endogenous mediators of preconditioning such as adenosine and bradykinin from endothelial cells, which may trigger a signalling cascade with an activation of kinases resulting in phosphorylation of endothelial nitric oxide synthase (eNOS) (22) and synthesis of eNOS and inducible nitric oxide synthase (iNOS) (8,16,22). Nitric oxide (NO) generated from these enzymes may subsequently activate guanylate cyclase and enhance the formation of cGMP (20,21). cGMP could activate PKG, which can subsequently open mitochondrial (15,21,22,29) and sarcolemmal (21) ATP-sensitive K+ (KATP) channels, resulting in acute and delayed cardioprotective effects. The role of PKG in sildenafil-induced protection against necrosis and apoptosis was abolished by the PKG inhibitors, KT5823, guanosine 3’5-cyclic monophosphorothioate, 8-(4-chlorophenylthio)(Rp-8-pCPT-cGMP) or DT-2 in cardiomyocytes. Moreover, the selective knockdown of PKG in cardiomyocytes with adenoviral vector containing short hairpin RNA of PKG also blocked sildenafil-induced protection. We further showed that sildenafil-induced phosphorylation of ERK1/2 and glycogen synthase kinase 3β, and sildenafil-enhanced Bcl-2/Bax ratio are blocked by KT5823 and short hairpin RNA of PKG (31). We, therefore, suggest that sildenafil (and, potentially, other PDE-5 inhibitors) may induce survival by NO synthesis-dependent cGMP accumulation and subsequent activation of PKG that leads to phosphorylation of ERK and inactivation of glycogen synthase kinase 3β.

Mitochondria are known to play an essential role in cell survival by ATP synthesis and maintenance of Ca2+ homeostasis. Opening the mitochondrial KATP channel partially compensates the membrane potential, which enables additional protons to be pumped out to form an H+ electrochemical gradient for both ATP synthesis and Ca2+ transport. The mitochondrial stabilizing effect of sildenafil was further confirmed in our isolated cardiomyocyte study (8), which showed an increase in the Bcl-2/Bax ratio and preservation of mitochondrial membrane potential in the sildenafil-pretreated myocytes. Nevertheless, the protective mechanisms for PDE-5 inhibitors given only at reperfusion appear to be independent of eNOS, inducible NO synthase and cGMP (26), but certainly require opening of the mitochondrial KATP channels (27). Calcium-activated potassium channels are K+-dselective, high-conductance channels that are critically dependent on intracellular Ca2+ flux and concentration. These channels are key mediators in cellular processes and are critical in maintaining Ca2+ homeostasis, mainly via their ability to sense transmembrane voltage and intracellular Ca2+ concentration (32). Recent studies have shown localization of these channels in the inner membrane of cardiomyocyte mitochondria (33). We recently showed that opening of mitochondrial calcium-activated potassium channels as well as mitochondrial KATP serve both as triggers and as mediators of sildenafil-elicited delayed cardioprotection (17).

Madhani et al (34) provided an interesting mechanism of protection: they showed that sildenafil-induced PKG-mediated phosphorylation of phospholamban at position 69 in cardiomyocytes during reperfusion is associated with the stimulation of the Na+/K+ -ATPase. The limitation of Na+ and Ca2+ overload as a result of increased Na+/K+ -ATPase could contribute to infarct limitation by attenuation of intracellular Na+ concentration accumulation during ischemia and/or reperfusion.

**VASCULAR ENDOTHELIAL DYSFUNCTION**

Endothelial dysfunction, defined as a reduction in the bioavailability of NO, is associated with many of the common risk factors for cardiovascular disease and, for instance, plays a major role in the development of atherosclerosis and acute coronary syndromes (35). Drugs, which are capable of improving endothelial function, usually provide benefits in reducing morbidity and mortality in patients suffering from ischemic heart disease. The effects of PDE-5 inhibitors on endothelial function have been extensively investigated in recent years. For example, in patients with chronic heart failure, acute administration of sildenafil increased endothelium-dependent, flow-mediated vasodilation in the brachial artery (36). It was also shown that sildenafil dilated the epicardial coronary arteries, improved endothelial dysfunction in the brachial artery, reduced exercise-induced ischemia and inhibited platelet activation in patients with coronary artery disease (37). Similarly, oral treatment with sildenafil in dogs caused vasodilation of coronary resistance vessels with an increase of blood flow into an ischemic myocardial region during exercise (38). A recent double-blind, placebo-controlled crossover study of healthy male volunteers (39) showed that sildenafil significantly reduced the impairment of endothelium-dependent vasodilation caused by pneumatic cuff-induced radial artery ischemia and reperfusion. Interestingly, the vasoprotective effect of sildenafil was abrogated by previous administration of sulphonyleurea glibenclamide, a KATP channel blocker, suggesting that opening of these channels played a crucial role, similar to protection against infarction in the intact heart. In contrast, a recent laboratory investigation (40) showed no change in coronary flow or myocardial oxygen consumption following sildenafil treatment in dogs with congestive heart failure at rest or during exercise. In addition, myocardial expression of PDE-5 protein was found to be downregulated in failing hearts, suggesting that this enzyme plays a minor role in the regulation of coronary hemodynamics in congestive heart failure (9,40).

**PULMONARY HYPERTENSION**

Pulmonary hypertension (PHT) is a rapidly progressive disease of the pulmonary vasculature, which subsequently leads to right heart failure. PHT is provoked by prolonged exposure to hypoxia, which leads to structural remodelling of pulmonary vessels, comprising increased thickness of the adventitial and medial layers, and muscularization of precapillary vessels (41). The combination of vasoconstruction and vascular remodelling, coupled with an increase in hematocrit triggered by hypoxia, results in PHT. Other illnesses, such as congenital heart disease, collagen vascular disease and HIV infection, are frequently associated with PHT. The lung is an organ with abundant PDE-5 expression (7). It has been shown that sildenafil attenuated the rise in pulmonary artery pressure and vascular remodelling when it was given before chronic exposure to hypoxia and during ongoing hypoxia-induced PHT in rats (42). Clinical investigations in patients with PHT also indicated that sildenafil therapy helps improve patients’ cardiac function and exercise capacity (43). Another study involving PHT patients showed that sildenafil significantly increased cardiac output and decreased pulmonary artery systolic pressure, mean pulmonary artery pressure, pulmonary vascular resistance and mean arterial pressure at peak measurements (44). In children with congenital heart disease, intravenous sildenafil was shown to be a pulmonary vasodilator that is as effective as inhaled NO (45). Sildenafil increases exercise capacity during severe hypoxia both at sea level and at high altitudes.
mitochondrial membrane potential, preserved myofibrillar integrity, and alleviated left ventricular dysfunction and ST segment prolongation. Similarly, in the isolated cardiomyocyte, doxorubicin treatment caused a significant increase in apoptosis, caspase-3 activation and disruption of mitochondrial membrane potential, all of which were attenuated by sildenafil. In addition, the protective effects were abolished by either L-NNAME (an inhibitor of NO synthase) or 5-HD (a blocker of mitochondrial K_{ATP}), indicating the participation of NO and mitochondrial K_{ATP} in mediating the protective effects of sildenafil against doxorubicin-induced cardiomyopathy (55). More recently, we showed that tadalafil also attenuated doxorubicin-induced cardiomyopathy in mice and prevented the depletion of prosurvival proteins including Bcl-2 and GATA-4 (36,57). In these studies, tadalafil given in combination with doxorubicin attenuated oxidative stress and improved antioxidant capacity via upregulation of mitochondrial superoxide dismutase. Interestingly, tadalafil did not interfere with the efficacy of DOX in killing human osteosarcoma cells in vitro or its antitumor effect in vivo in a tumor xenograft model.

STROKE AND NEURODEGENERATIVE DISEASES
PDE-5 inhibitors may also protect the brain against stroke and other neurodegenerative diseases. Oral treatment with sildenafil for seven consecutive days starting 2 h or 24 h after embolic middle cerebral artery occlusion significantly enhanced neurological recovery without any effect on infarct volume (38). The authors proposed that an increase in the cortical levels of cGMP after sildenafil treatment may have evoked neurogenesis and reduced neurological deficits. Sildenafil has also been shown to influence cerebral hemodynamics during acute exposure to high altitudes and after acclimatization (59). Cerebral oxygenation was significantly enhanced with sildenafil in subjects after rapid ascent to 3480 m as demonstrated by an improvement in several physiological parameters such as cerebral oxygen saturation, regional cerebral oxygen saturation and middle cerebral artery velocity. Improvement in cerebral oxygenation with sildenafil was also observed in children with elevated pulmonary vascular resistance due to congenital heart defects after cardiac surgery (60). There was a significant increase in cerebral oxygenated hemoglobin and total hemoglobin, and a decrease in deoxygenated hemoglobin following sildenafil administration. These changes in hemoglobin elevated the cerebral tissue oxygenation index, probably due to general endothelial dysfunction after cardiopulmonary bypass. These findings may be clinically important because they indicate that sildenafil may increase cerebral blood flow through amelioration of general endothelial dysfunction after cardiopulmonary bypass surgery (60). Similar cerebral vascular-protective effects of sildenafil were recently reported in 11 patients suffering from severe PHT and 22 healthy volunteers (61). Both groups inhaled iloprost (a commonly used drug to treat PHT) and oral sildenafil, which led to a significant reduction in pulmonary arterial pressure and vascular resistance, accompanied by minor changes in systemic vascular resistance. The cerebral vascular tone and microvascular reactivity were significantly improved by sildenafil, but slightly worsened by iloprost. Taken together, these studies suggest a potential use of PDE-5 inhibitors to improve cerebral circulation, particularly under hypoxic conditions.

OTHER NONUROLOGICAL USES
Sildenafil may also offer a potential therapeutic strategy to improve uteroplacental blood flow in fetal growth restriction (FGR). FGR affects up to 5% of all pregnancies and has massive health implications including morbidity, mortality and increased incidence of cardiovascular disease in adulthood. Sildenafil treatment reduced vasoconstriction and improved relaxation of small vessels in women whose pregnancies were complicated by FGR (62). Patients suffering from liver cirrhosis may also benefit from sildenafil therapy in the future. Hyperammonemia (elevated ammonia levels in the blood) appears to contribute to mental deficits and other neurological abnormalities in cirrhosis patients. The

Kukreja et al
underlying molecular mechanism appears to be related to the impaired function of the glutamate-NO-cGMP pathway in the brain. It has been shown that chronic oral administration of sildenafil normalized the glutamate-NO-cGMP pathway and extracellular cGMP in the brain of rats with portacaval anastomosis or hyperammonemia. Moreover, sildenafil restored the ability of rats with hyperammonemia or with portacaval shunts to learn a conditional discrimination task (63).

It has been shown that human coronary arteriolar endothelial cells exposed to sildenafil (1 µM to 20 µM) demonstrated significantly accelerated tubular morphogenesis with the induction of thioxedrin-1, hemoxygenase-1 and vascular endothelial growth factor (VEGF).

Sildenafil induced VEGF and angiopoietin-specific receptors such as KDR, Tie-1 and Tie-2 (64). These authors also showed that sildenafil protected the heart against ischemia-reperfusion injury by upregulating VEGF and the Ang-1 system (65). Other studies have shown that both sildenafil and vardenafil enhance ischemia-induced angiogenesis as measured by vascular perfusion, tissue blood flow and vascular density in a mouse model of unilateral hindlimb ischemia (66,67). Thus, PDE-5 inhibitors may have therapeutic potential in treating ischemic cardiovascular diseases such as peripheral artery disease and critical limb ischemic patients.

Because of the potent systemic vasodilatory effects of PDE-5 inhibitors, these drugs may be beneficial in patients with Raynaud’s phenomenon. It has been shown that vardenafil (10 mg by mouth, twice daily), when given to patients with Raynaud’s disease, improved digital blood flow in 70% of patients and improved clinical symptoms in 68% of patients (68). Sildenafil also reduced the frequency and duration of Raynaud attacks, and markedly increased capillary blood flow velocity with visible healing of chronic digital ulcers in patients (69). However, similar benefits were not observed with tadalafil (70,71). Thus, sildenafil may be a promising agent for the treatment of Raynaud patients in the future.

**FUTURE PERSPECTIVE**

The studies reviewed above suggest that PDE-5 inhibitors have great promise for further development as novel drug therapies for MI, cardiac hypertrophy, cardiomyopathy, heart failure, stroke, neurodegenerative diseases and, potentially, other circulatory disorders (Figure 1).

**REFERENCES**


**ACKNOWLEDGEMENTS:** This study was supported by grants from the National Institutes of Health (HL51465, HL7424 and HL93685) to Rakesh C. Kukreja and a National Scientist Development Grant from the American Heart Association (11POST740028).


